OnTarget™ separates tumor DNA from wild-type using our novel molecular separation technology to overcome the challenges facing conventional assays in detection of low abundance tumor mutations from tissue or plasma.
In about an hour and without sample splitting, targeted mutations are enriched and separated from wild-type DNA. These can then be easily detected by PCR or next generation sequencing platforms to provide an efficient, highly sensitive and multiplexed mutation detection assay.
At Boreal, we have a simple, yet innovative solution. We take the haystack, keep the needles, and throw out the hay.
OnTarget™ removes wild-type molecules from the sample that give rise to false positives, and targets DNA for analysis to tumor content only. Limiting background DNA not only greatly improves sensitivity and specificity of subsequent mutation detection with PCR or NGS assays, but also increases utilization of assay resources. The diagram above follows rare tumor mutations present at only 0.01% of total DNA through detection using PCR or next generation sequencing. OnTarget™ enrichment eliminates false positive error in detection to enable accurate and quantifiable identification of low abundance mutations.
Boreal has developed a highly selective method of molecular separation that allows enrichment of nucleic acid sequences to single base accuracy. OnTarget™ uses a synchronous thermal-electrophoretic separation technology to remove virtually all wild-type alleles from a sample prior to analysis. Without amplification and generation of new nucleic acid strands, this greatly improves the ratio of target allele to wild-type DNA, making subsequent detection of mutations simple and accurate.
This unique approach to enrichment also means that OnTarget™ can analyze short, degraded, or damaged DNA fragments from blood and FFPE that would be missed by other methods – accessing more signal from precious samples.
Boreal has developed an optimized end-to-end assay for DNA extraction followed by OnTarget™ enrichment and mutation detection with PCR or sequencing platforms. Using conventional methods for DNA extraction that have been optimized for recovery of low abundance nucleic acids, OnTarget™ can process FFPE tissue or any volume of plasma available to maximize mutation signal.
As OnTarget™ removes all wild-type molecules from the sample during enrichment, Boreal has developed a technique to spike in markers that provide a truly quantitative readout of mutation abundance relative to the original sample. OnTarget™ offers single molecule sensitivity making it the most sensitive, quantitative, mutation detection assay available today.
OnTarget™ can recover hundreds of unique targets in parallel without sample splitting, maximizing assay sensitivity. This is critical for detection of mutations in samples with limited signal including plasma and degraded or low tumor content tissue.